Contact Us

News & Media

Recent Press

SK pharmteco’s subsidiary Yposkesi launches AAVelocity, a plug-and-play Adeno-Associated Virus (AAV) platform

Designed to shorten turnaround on manufacturing AAVs, this new platform offers Cell and Gene Therapy developers more flexibility in producing viral vectors for clinical and commercial use

November 7, 2023

SK pharmteco to Expand Capabilities with Acquisition of Controlling Interest in Center for Breakthrough Medicines

SK Pharmteco Expands Capabilities with Majority Stake of Center for Breakthrough Medicines

September 20, 2023

Center for Breakthrough Medicines Now Provides a Clinically Tested Adherent Manufacturing Platform for AAV Production

CBM is the Exclusive CDMO Provider of an iCellis 500-based
Adeno-Associated Virus (AAV) Adherent Platform developed by the Gene Therapy Program at the University of Pennsylvania

April 12, 2023

Cell One Partners and Center for Breakthrough Medicines Announce Strategic Partnership to Accelerate Cell and Gene Therapy Commercialization

Cell One Partners and Center for Breakthrough Medicines Announce Strategic Partnership to Accelerate Cell and Gene Therapy Commercialization

March 9, 2023

Center for Breakthrough Medicines, Nucleus Biologics, and Stoic Bio Announce Strategic Collaboration for Steady Supply of Quality Controlled Cell Culture Media to Expedite Development of Cell and Gene Therapies

Center for Breakthrough Medicines, Nucleus Biologics, and Stoic Bio Announce Strategic Collaboration for Steady Supply of Quality Controlled Cell Culture Media to Expedite Development of Cell and Gene Therapies

March 7, 2023

Center for Breakthrough Medicines Offers Pre-clinical Packages with Plasmids, Cell Line, and Pre-clinical Vector Manufacturing with Capacity Available Now

Center for Breakthrough Medicines Offers Pre-clinical Packages with Plasmids, Cell Line, and Pre-clinical Vector Manufacturing with Capacity Available Now

February 28, 2023